, while Hb CS, Hb QS and codon 30 (DGAG) were identified by single-tube multiplex amplification refractory mutation system (ARMS). Automated direct nucleotide sequencing of the amplified a2-and a1-globin genes was performed to characterise other non-deletional a-thalassaemia determinants. Results: In the 100 cases studied, 99 cases had 22 SEA in combination with deletional a + -thalassaemia or non-deletional a-globin gene mutation involving the a2-globin gene. In 70 cases of the deletional form, 43 cases showed the genotype of (22 SEA /2a 3.7 ) and 27 cases of (22 SEA /2a 4.2 ). Three of the 27 cases of (22 SEA /2a 4.2 ) were found to have Hb Q-Thailand linked in-cis with 2a 4.2 . The remaining 30 cases were of non-deletional form with the following genotypes: 11 cases of (22 SEA /a HbCS a), 9 cases of (22 SEA /a HbQS a), 3 cases of (22 SEA /a cd30 (DGAG) a), 3 cases of (22 SEA /a cd31 a), 2 cases of (22 SEA /a poly-A a), 1 case of (22 SEA /a HbWestmead a) and 1 case of (22 non-SEA /a HbQS a). Conclusions: Based on two rapid diagnostic tests, multiplex gap-PCR and multiplex ARMS, more than 90% of the cases were genetically characterised. This laboratory strategy should be widely applicable for genetic diagnosis of a-thalassaemia.
T he a-thalassaemia syndromes represent a common genetic disorder due to an absence or diminished synthesis of a globin chain of the haemoglobin (Hb) molecule. The human globin gene cluster is located on chromosome 16p13.3-pter. This cluster contains three genes and four pseudogenes arranged as follows: 59 f2-yf1-ya2-ya1-a2-a1-h1 39. a-Thalassaemia frequently results from deletions of aglobin genes. Non-deletional mutations involving single to a few nucleotides within the structural genes account for a small proportion of cases. 1 2 a-Thalassaemia traits are caused by deletion or nondeletional mutation of one (2a/aa, a T a/aa or aa T /aa) or two (22/aa or 2a/2a) a-globin genes. Patients with Hb H disease show loss or inactivation of three a-globin genes (22/2a or 22/a T a or 22/aa T ). They have a moderately severe haemolytic anaemia with a variable clinical course. In Hb Bart's hydrops fetalis (22/22), severe intrauterine anaemia develops that results in fetal death at or around the time of birth. 1 3 4 Population studies have indicated that the types and frequencies of the different a-thalassaemia defects vary among different ethnic groups. 1 In Hong Kong, the commonest a˚-thalassaemia determinant is the South East Asian deletion (22 SEA ) which removes nearly 20 kb DNA of the a-globin gene cluster. 5 The common a + -thalassaemia determinants are the rightward deletion (2a 3.7 ) and leftward deletion (2a 4.2 ). 5 6 The more common non-deletional a2-thalassaemia determinants include Hb Constant Spring (Hb CS), Hb Quong Sze (Hb QS) and codon 30 (DGAG). 5 6 As Hb H disease follows a variable clinical course ranging from asymptomatic to multi-organ morbidity, the latter more associated with non-deletional forms, there is a rationale for early and accurate diagnosis of Hb H disease at the genotypic level prior to onset of complications. Improved patient care for patients with high risk Hb H disease may be achieved with laboratory and clinical monitoring. In this study, we present a rapid and simple laboratory approach for molecular diagnosis of Hb H disease.
MATERIALS AND METHODS

Patient samples
Between 1998 and 2003, 100 cases of Hb H disease (97 Chinese, 2 Thais, 1 Filipino) were diagnosed by routine haemoglobin study. Seven cases were related, coming from three families with Hb H disease. The age range was 1-84 years, with more than two-thirds of the patients older than 20 years and onethird older than 40 years.
DNA analysis
Genomic DNA was extracted from peripheral blood of patients. Multiplex gap-PCR 7 was adopted and modified to detect 22 SEA , 2a 3.7 and 2a 4.2 . Genomic DNA samples were amplified in a GeneAmp9700 thermocycler using the following cycling parameters: initial denaturation at 95˚C for 15 min, followed by 30 cycles of 98˚C denaturing for 45 s, 60˚C annealing for 1 min 30 s, and 72˚C extension 2 min 15 s. A final 5 min extension completed the reaction. Each PCR was set up in a total volume of 50 ml containing: 300-600 ng genomic DNA, 200 mM of each dNTP, 1.5 mM MgCl 2 , 16 Q-solution (Qiagen, Hilden, Germany), 2.5 U HotStarTaq DNA polymerase in supplied reaction buffer (Qiagen) and 9 different primers at various concentrations (table 1) . A 10 ml aliquot of each amplified product was analysed by electrophoresis on a 1% agarose gel after staining with ethidium bromide.
For the detection of the three common non-deletional a2-thalassaemia determinants, Hb CS, Hb QS and codon 30 (DGAG), the multiplex amplification refractory mutation Abbreviations: ARMS, amplification refractory mutation system; Hb, haemoglobin 931 www.jclinpath.com on 13 October 2008 jcp.bmj.com system (ARMS) 8 approach was modified and used. Genomic DNA samples were amplified in a GeneAmp9700 thermocycler using the following cycling parameters: initial denaturation at 94˚C for 12 min, followed by 32 cycles of 94˚C denaturing for 40 s, 62˚C annealing for 20 s, and 72˚C extension 3 min. A final 7 minutes extension completed the reaction. Each PCR was set up in a total volume of 20 ml containing: 200 mM of each dNTP, 2.0 mM MgCl 2 , 10% dimethysulphoxide, 16.5 mM ammonium sulphate, 0.01% (w/v) gelatin, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 U AmpliTaq Gold DNA polymerase and 6 different primers at various concentrations (table 1). A 10 ml aliquot of each amplified product was analysed by electrophoresis on a 8% non-denaturing polyacrylamide gel after staining with ethidium bromide.
Automated direct nucleotide sequencing (ABI 377, Applied Biosystems, Foster City, California, USA) of the amplified a2-and a1-globin genes was performed to characterise other nondeletional a-thalassaemia determinants. 9 Figure 2 shows the electrophoretic results of multiplex gap-PCR product in deletional Hb H disease on 1% agarose gel. Three cases of (22 SEA /2a 4.2 ) were also found to have Hb QThailand 10 11 linked in-cis with 2a 4.2 by direct nucleotide sequencing of the amplified a1-globin gene.
RESULTS
Among the remaining 30% of cases with Hb H disease, six different types of non-deletional determinants were found, all in the a2-globin gene. They were Hb CS, Hb QS, codon 30 (DGAG), 12 codon 31 (AGGRAAG), 13 poly-A signal (AATAAARAATGAA) 14 and Hb Westmead (codon 122 CACRCAG). 14 15 Our multiplex ARMS detected Hb CS, Hb QS and codon 30 (DGAG) and resolved 80% (ie 24/30) of the nondeletional cases. Figure 3 shows the electrophoretic results of three common non-deletional Hb H disease as detected by our multiplex ARMS in an aqueous 8% polyacrylamide gel.
The remaining three non-deletional determinants were characterised by direct nucleotide sequencing of the amplified a2-globin gene. They were codon 31 (AGGRAAG), 13 poly-A signal AATAAARAATGAA 14 and Hb Westmead (codon 122 CACRCAG). 14 15 Figure 4 illustrates the automated sequencing result of codon 31 (AGGRAAG).
DISCUSSION
The clinical severity of Hb H disease is known to be variable. There is evidence to show a more severe phenotype with non-deletional forms (22/a T a) compared with deletional forms (22/2a), 3 4 16-18 which leads to the view that Hb H disease is not as benign a disorder as previously thought. 18 Patients with non-deletional forms of Hb H may have significant anaemia, iron overload and multi-organ morbidity. An early and accurate diagnosis of Hb H disease is therefore warranted. Many methods for genetic diagnosis of a-thalassaemia are currently in use, including Southern blot analysis, direct nucleotide sequencing and reverse dot-blotting. 19 However, these approaches are labour-intensive and time-consuming. With our diagnostic strategy (fig 1) , more than 90% of Hb H disease in our population can be characterised by performing only two multiplex PCRs, and direct sequencing is needed in ,10% of cases. With adaptation to detect prevalent aglobin mutations in their localities, our approach should also be applicable in other South East Asian countries. This strategy can be further modified by including primers for the detection of the 22
MED and 2(a) 20.5 double-gene deletions and becomes applicable in the Mediterranean area. 7 However, this strategy may be less applicable in places like Cambodia or Papua New Guinea where access to fluorescent dye chemistry sequencing is much more limited.
Prenatal diagnosis for Hb H disease is not routinely performed as it is not generally regarded as a severe condition. Whether genetic risk prediction is indicated for a non-fatal disorder that is associated with significant morbidity, such as Hb H disease, will have to be considered in light of recent evidence of more severe forms of the disease, such as Hb H hydrops. 16 However, current antenatal thalassaemia screening does not usually identify couples at risk of Hb H disease because 2a 4.2 or 2a 3.7 heterozygous carrier state cannot be reliably detected by phenotypic tests. Hence genetic counselling will not be offered even if Hb H disease is included as a target for screening.
The availability of a simple and effective a-thalassaemia genotyping strategy as proposed in the present study will greatly facilitate carrier detection and its potential use in antenatal screening, molecular characterisation of Hb H disease, genotype-phenotype correlation as well as longitudinal studies on the natural history of clearly defined deletional and non-deletional Hb H disease. N Automated direct nucleotide sequencing of the amplified a2-and a1-globin genes was performed to characterise other non-deletional a-thalassaemia determinants.
N Based on two rapid diagnostic tests, namely multiplex gap-PCR and multiplex ARMS, .90% of the cases were genetically characterised. N This laboratory strategy should be widely applicable for genetic diagnosis of a-thalassaemia.
